Chinese cardiologists evaluated the effect of Xiongshau Capsule (XS) in preventing clinical and angiographic restenosis after coronary angioplasty and/or stenting. A total of 108 coronary heart disease patients with successful coronary angioplasty and/or stenting were randomly divided into the control group (55 cases, routine treatment) and the XS group (53 cases, routine treatment plus XS). The recurrence of angina, clinical endpoint events, changing of blood-stasis syndrome score (BSSS) and coronary angiography within 6 months of coronary angioplasty and/or stenting were observed. Follow-up angiography was performed in 42 patients, including 18 cases in the XS group (restenosis was observed in 17 patients), there was a significant difference between the occurrence of restenosis in XS and in control groups. The occurrence of clinical endpoints (death, non-fatal target lesion, myocardial infarction, coronary artery bypass graft surgery or repeat target-vessel angioplasty) in the XS group (18.8%) was significantly lower than that in the control group (40%). There was a significant difference in the recurrence of angina observed in the XS group (13 cases) compared with the control group (27 cases). There was also remarkable significance for the difference between baseline and follow-up BSSS between the groups. Logistic multivariate stepwise regression analysis and multivariate regression analysis of the related factors with restenosis confirmed by coronary angiography showed that the baseline BSSS and the difference between baseline and follow-up BSSS were important influencing factors on the occurrence of restenosis after interventional treatment.